Okyo Pharma Ltd - UK-based ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease - Delays delisting from London Stock Exchange until May 22. Was previously due on Friday. Says this will have no effect on its American depositary shares trading on Nasdaq in New York. In April, it said the decision to cancel its listing was due to the number of shares trading being "negligible and does not justify the associated costs".
Current stock price: 2.22 pence, up 5.7%
12-month change: down 64%
By Greg Rosenvinge, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.